Welcome to our dedicated page for Jaguar Health news (Ticker: JAGX), a resource for investors and traders seeking the latest updates and insights on Jaguar Health stock.
Jaguar Health, Inc. (NASDAQ: JAGX) is a commercial-stage pharmaceuticals company specializing in the development of novel prescription medicines sustainably derived from natural plant sources in rainforest areas. The company's primary focus is on addressing gastrointestinal (GI) distress in both humans and animals, with an emphasis on chronic debilitating diarrhea and associated symptoms such as urgency, bowel incontinence, and cramping pain.
Jaguar Health operates through several subsidiaries, including Napo Pharmaceuticals, Inc., which develops and commercializes proprietary human GI pharmaceuticals globally. One of its flagship products, Mytesi® (crofelemer), is FDA-approved for symptomatic relief of noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy. The company’s lead animal prescription drug candidate, Canalevia™, targets forms of diarrhea in dogs, while Equilevia™ supports total gut health in equine athletes.
In addition, Jaguar Health, through its Napo Pharmaceuticals subsidiary, is advancing the development of crofelemer with the ongoing OnTarget study, a pivotal Phase 3 clinical trial aimed at the preventive treatment of chemotherapy-induced overactive bowel (CIOB) in adults with cancer on targeted therapy. Crofelemer has also been designated an Orphan Drug by the FDA and European Medicines Agency for short bowel syndrome (SBS) and microvillus inclusion disease (MVID).
Jaguar Health’s commitment to cancer supportive care is showcased through its preparation to launch Gelclair®, an FDA-approved oral mucositis prescription product, in Q3 2024. This initiative is part of their broader strategy to support cancer patients facing severe treatment side effects.
Beyond GI distress, Jaguar Health has a joint venture called Magdalena Biosciences, in collaboration with Filament Health Corp. This venture focuses on developing plant-based prescription medicines for mental health indications. A recent out-licensing agreement with Magdalena includes a botanical drug candidate for potential schizophrenia and psychoses indications.
Jaguar Health’s financial performance reflects consistent growth, with Q1 2024 revenue at approximately $2.4 million, showing a 20% increase from Q1 2023. Despite operational losses, the company continues to invest in research and development, particularly for rare disease treatments.
For more information, visit Jaguar Health, Napo Pharmaceuticals, Napo Therapeutics, and Magdalena Biosciences. Stay connected with Jaguar Health on LinkedIn, X (formerly Twitter), and Instagram.
Jaguar Health, Inc. (NASDAQ:JAGX) announced that it received an extension from the Nasdaq Hearings Panel until December 23, 2020, to comply with the minimum bid price requirement for continued listing. The company must maintain a bid price of at least $1.00 per share for ten consecutive business days. Jaguar's recent efforts include expanded access programs for Mytesi and a $6 million royalty-based capital infusion. Additionally, Napo Pharmaceuticals initiated a pivotal Phase 3 trial for Mytesi in adult cancer patients experiencing diarrhea.
Jaguar Health (NASDAQ:JAGX) is hosting its inaugural "Diarrhea Dialogues" virtual event on October 20, 2020, from 3:00 PM to 4:30 PM ET, focused on supportive care for cancer patients experiencing diarrhea from cancer therapies. Key experts, including Jaguar's leadership and oncologists, will discuss the impact of diarrhea on cancer treatment and the importance of patient-physician dialogue. Jaguar's subsidiary, Napo Pharmaceuticals, has initiated a pivotal Phase 3 trial for crofelemer (Mytesi) in preventing cancer therapy-related diarrhea, currently approved for HIV/AIDS-related diarrhea relief.
Jaguar Health, Inc. (NASDAQ:JAGX) granted nonstatutory stock options for 45,000 shares to a new employee effective October 13, 2020. The options, at an exercise price of $0.315 per share, are part of the Company's Inducement Award Plan and aim to incentivize new hires. The options vest 25% after nine months and monthly thereafter over the next 27 months, contingent on continued employment. Jaguar Health specializes in plant-based gastrointestinal products, with its MYTESI product approved by the U.S. FDA for treating noninfectious diarrhea in adults with HIV/AIDS on antiretroviral therapy.
Napo Pharmaceuticals, a subsidiary of Jaguar Health (NASDAQ:JAGX), unveiled the iAssist platform as part of its NapoCares patient support program. This web-based system automates the prescription process for Mytesi (crofelemer), an FDA-approved, plant-based treatment for diarrhea in HIV/AIDS patients. The platform enhances patient access by simplifying e-prescribing, prior authorizations, and eligibility checks, thereby promoting quicker treatment initiation. AssistRx developed iAssist, which also aids in tracking patient status and managing communications among healthcare providers, patients, and payers.
Jaguar Health has appointed Melissa Yeager, J.D. as Senior Vice President of Regulatory Affairs & Quality Assurance. With extensive experience in the pharmaceutical industry, Yeager's leadership is expected to enhance the regulatory and quality functions at Jaguar and its subsidiary, Napo Pharmaceuticals. This move supports the ongoing commercialization of Mytesi and the pivotal Phase 3 clinical trial for diarrhea prophylaxis in adult cancer patients. Mytesi, a plant-based, FDA-approved antidiarrheal, assists patients with HIV/AIDS on antiretroviral therapy.
Jaguar Health, Inc. (NASDAQ:JAGX) has successfully closed the first $6 million tranche of a non-dilutive royalty financing transaction, potentially totaling $17 million, to support ongoing clinical trials for Mytesi (crofelemer). This financing will aid in developing treatments for cancer therapy-related diarrhea. Additionally, Jaguar has amended its agreement with Oasis Capital, allowing for $2,117,875.20 in accounts receivable purchases. The company aims to achieve financial sustainability in 2021 and has seen a 378% increase in Mytesi's Q2 2020 sales compared to Q1.
Jaguar Health, through its subsidiary Napo Pharmaceuticals, has launched a pivotal Phase 3 trial for crofelemer (Mytesi) aimed at preventing diarrhea in adult cancer patients undergoing targeted therapy. This 24-week, randomized, placebo-controlled study aims to address a significant unmet need as diarrhea affects over 650,000 chemotherapy patients in the U.S. annually. The trial is supported by an increased non-dilutive financing deal, now totaling $17 million, anticipated to expedite patient enrollment and site activation. Mytesi is FDA-approved for HIV/AIDS-related diarrhea, showcasing its therapeutic potential.
Jaguar Health (NASDAQ:JAGX) announced that it has met the financial condition for an initial $5 million tranche of a potential $16 million non-dilutive royalty financing transaction. This financing is designed to support its development pipeline, particularly funding a pivotal clinical trial for Mytesi (crofelemer) aimed at treating cancer therapy-related diarrhea. The company has initiated an at-the-market program with Ladenburg Thalmann for future financing needs and anticipates the trial to start in Q4 2020.
Jaguar Health (NASDAQ:JAGX) announced a non-dilutive royalty financing agreement with a secured lender, securing $5 million for future royalties on Mytesi (crofelemer) sales. This funding will support regulatory activities, including a pivotal clinical trial for cancer therapy-related diarrhea (CTD), expected to commence in Q4 2020. The agreement may allow for additional financing up to $16 million by July 2021. CEO Lisa Conte emphasized that this option will not dilute shareholder equity and is based on the growing sales of Mytesi for HIV-related diarrhea.
Jaguar Health (NASDAQ:JAGX) announced that its subsidiary, Napo Pharmaceuticals, is sponsoring the National Trans Visibility March (NTVM) starting September 28, 2020. In conjunction with this event, Napo will host a virtual workshop on the gastrointestinal (GI) consequences of HIV on September 30, 2020, led by advocate Marissa Miller. Jaguar focuses on plant-based, non-opioid medicines for GI distress, with its product Mytesi approved for treating noninfectious diarrhea in HIV/AIDS patients. The company emphasizes its commitment to health equity and support for marginalized communities.
FAQ
What is the current stock price of Jaguar Health (JAGX)?
What is the market cap of Jaguar Health (JAGX)?
What is Jaguar Health, Inc.?
What are the main products of Jaguar Health?
What is Mytesi® used for?
What is the OnTarget study?
What recent achievements has Jaguar Health made?
What is the focus of Magdalena Biosciences?
What are the financial highlights for Jaguar Health in Q1 2024?
What sustainability practices does Jaguar Health follow?
How can I stay updated on Jaguar Health's developments?
What is Gelclair® and its use?
